Filip V. D. B.
- Country
- Belgium
- Department
- N/A
Research Overview
- Evaluation of ERAP Inhibition in Patients with Axial Spondyloarthritis: The EAST-1 Clinical Trial
- A Phase II Study of MK-1045 in Patients with Systemic Lupus Erythematosus or Rheumatoid Arthritis
- A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
Data & Insights
Has run more than one trial at 156 of 317 partner sites.
Specializations
Inflammatory Arthritis
This investigator specializes in the treatment of rheumatoid arthritis, conducting research into advanced therapeutic approaches for patients with moderate to severe disease. Their work focuses on evaluating novel treatment options for patients who have shown inadequate response to conventional therapies.
- Treatment-resistant rheumatoid arthritis
- Novel therapeutic agents
- Background methotrexate therapy
Spondyloarthritis
The investigator has significant expertise in axial spondyloarthritis and its variants, including both radiographic and non-radiographic forms. Their research encompasses innovative approaches to disease management and remission strategies.
- Non-radiographic axial spondyloarthritis
- Peripheral spondyloarthritis
- Remission-induction strategies
Psoriatic Disease
The investigator conducts extensive research in psoriatic arthritis, exploring various therapeutic approaches for patients with active disease. Their work includes evaluation of treatment options for both biologic-naïve patients and those with previous biologic exposure.
- Active psoriatic arthritis
- Biologic therapy response
- Treatment-resistant cases
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.